{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:43:01Z","timestamp":1790185381420,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.fjurol.2025.103010","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:29:50Z","timestamp":1760660990000},"page":"103010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["French recommendations from the AFU Cancer Committee for prostate cancer: 2025 summary of changes"],"prefix":"10.1016","volume":"35","author":[{"given":"Guillaume","family":"Ploussard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Rozet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eble","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2025.103010_bib0155","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jama.2025.13722","article-title":"Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial","volume":"334","author":"Ng","year":"2025","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.fjurol.2025.103010_bib0160","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2025.3579","article-title":"Microultrasonography-guided vs mri-guided biopsy for prostate cancer diagnosis: the OPTIMUM randomized clinical trial","volume":"333","author":"Kinnaird","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.fjurol.2025.103010_bib0165","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(25)00100-7","article-title":"Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial","volume":"26","author":"Bryant","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.103010_bib0170","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2024.10.006","article-title":"Pelvic lymph node dissection in prostate cancer: update from a randomized clinical trial of limited versus extended dissection","volume":"87","author":"Touijer","year":"2025","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.fjurol.2025.103010_bib0175","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.fjurol.2025.103010_bib0180","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2024.11.006","article-title":"Whole-gland or subtotal high-intensity focused ultrasound versus radical prostatectomy: the prospective, noninferiority, nonrandomized HIFI trial","volume":"87","author":"Ploussard","year":"2025","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2025.103010_bib0185","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2025.103010_bib0190","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.fjurol.2025.103010_bib0195","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO-25-00131","article-title":"Outcomes of Radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: the RAVENS phase II randomized trial","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.fjurol.2025.103010_bib0200","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.fjurol.2025.103010_bib0205","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300251","article-title":"Enzalutamide and quality of life in biochemically recurrent prostate cancer","volume":"2","author":"Freedland","year":"2023","journal-title":"NEJM Evid"},{"issue":"5","key":"10.1016\/j.fjurol.2025.103010_bib0210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2025.02.006","article-title":"Effects of enzalutamide on the sexual activity of patients with biochemically recurrent prostate cancer: a post hoc analysis of patient-reported outcomes in the EMBARK study","volume":"87","author":"Freedland","year":"2025","journal-title":"Eur Urol"},{"issue":"10467","key":"10.1016\/j.fjurol.2025.103010_bib0215","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2025.103010_bib0220","article-title":"Impact of prostate radiotherapy on survival outcomes in patients with metastatic castration-sensitive prostate cancer: a meta-analysis of randomized phase 3 clinical trials","author":"Yazgan","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"36","key":"10.1016\/j.fjurol.2025.103010_bib0225","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.fjurol.2025.103010_bib0230","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(25)00231-1","article-title":"Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol","volume":"26","author":"Gillessen","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2025.103010_bib0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","author":"Attard","year":"2025","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.fjurol.2025.103010_bib0240","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1470-2045(25)00351-1","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Niazi","year":"2025","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.fjurol.2025.103010_bib0245","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10459","key":"10.1016\/j.fjurol.2025.103010_bib0250","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2025.103010_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","author":"Fizazi","year":"2025","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2025.103010_bib0260","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","article-title":"Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial","volume":"26","author":"Fizazi","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10502","key":"10.1016\/j.fjurol.2025.103010_bib0265","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"issue":"10502","key":"10.1016\/j.fjurol.2025.103010_bib0270","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.fjurol.2025.103010_bib0275","doi-asserted-by":"crossref","first-page":"115078","DOI":"10.1016\/j.ejca.2024.115078","article-title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study","author":"Azad","year":"2024","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.fjurol.2025.103010_bib0280","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(25)00031-2","volume":"26","author":"Fay","year":"2025","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2025.103010_bib0285","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1470-2045(25)00030-0","article-title":"First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"26","author":"Matsubara","year":"2025","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.fjurol.2025.103010_bib0290","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2025.103010_bib0295","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2025.103010_bib0300","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:46:34Z","timestamp":1790178394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393025001573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950393025001573"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.103010","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French recommendations from the AFU Cancer Committee for prostate cancer: 2025 summary of changes","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.103010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103010"}}